BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase III data

Top-line data from the double-blind Phase III OCEANS trial in 484 patients with platinum-sensitive recurrent ovarian cancer showed that 15 mg/kg IV Avastin every 3 weeks plus carboplatin and Gemzar gemcitabine followed by Avastin maintenance therapy met the primary endpoint of significantly improving PFS vs. placebo plus chemotherapy followed by no maintenance therapy. Roche also said the European Medicines Agency...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >